Table 2.

Analysis of survival time of Smad4-positive and Smad4-negative patients stratified with regard to tumor stage, ER-status, TβRI-status, and TβRII-status. 5-year survival rates were computed by the Kaplan-Meier estimator. Survival curves were compared by log-rank test (n = 197).

	5 year survival		Total number		Log rank test
					Number censored		p
	Smad4 negative	Smad4 positive	Smad4 negative	Smad4 positive	Smad4 negative	Smad4 positive
Unstratified	92.4	74.5	44	153	35	111	0.187
WHO I	100.0*	86.7	11	24	11	19	0.135
WHO II	94.4	81.3	19	89	15	71	0.821
WHO III	92.3	54.7	13	34	9	19	0.137
WHO IV	0	20.8	1	6	0	2	0.661
WHO I/II	96.2	82.5	30	113	26	90	0.32
WHO III/IV	84.4	50.2	14	40	9	21	0.121
T1	100.0	83.7	15	37	14	29	0.209
T2	93.3	71.2	15	84	11	57	0.448
T3	87.5	63.5	8	12	5	8	0.899
T4	50.0	45.5	6	20	2	9	0.588
N0	94.1	88.1	18	64	16	52	0.425
N1	91.1	59.0	23	77	15	45	0.167
N2	50.0	52.5	2	8	1	4	0.666
N3	0	50.0	1	4	0	2	0.948
N1–3	84.3	57.9	26	89	16	51	0.227
ER negative	93.8	66.5	16	59	13	41	0.278
ER positive	91.7	78.9	28	94	22	70	0.474
TβRI negative	94.1	76.5	17	24	16	19	0.245
TβRI positive	92.3	74.1	27	129	19	92	0.523
TβRII negative	100.0	80	19	39	17	30	0.133
TβRII positive	85.9	72.8	25	114	18	81	0.806

* survival times could not be computed as all cases were censored